Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9UHC

FGFR1 kinase domain with a covalent inhibitor 9p

これはPDB形式変換不可エントリーです。
9UHC の概要
エントリーDOI10.2210/pdb9uhc/pdb
分子名称Fibroblast growth factor receptor 1, ~{N}-[1-methyl-3-[2-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]-5~{H}-pyrrolo[2,3-b]pyrazin-7-yl]indol-6-yl]propanamide, SULFATE ION, ... (4 entities in total)
機能のキーワードfibroblast growth factor receptor 1, transferase inhibitor, transferase
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計72102.58
構造登録者
Chen, X.J.,Chen, Y.H. (登録日: 2025-04-14, 公開日: 2025-09-24, 最終更新日: 2025-10-08)
主引用文献Deng, W.,Chen, X.,Yan, L.,Xiang, S.,Song, X.,Zhang, L.,Li, X.,Zhu, W.,Pei, J.,Lin, X.,Patterson, A.V.,Smaill, J.B.,Li, B.,Tu, Z.,Zhou, Y.,Chen, Y.,Lu, X.
Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1 H -indole-3-yl)-5 H -pyrrolo[2,3- b ]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance.
J.Med.Chem., 68:19415-19437, 2025
Cited by
PubMed Abstract: Aberrant activation of fibroblast growth factor receptors (FGFRs) plays a critical role in tumorigenesis across multiple cancer types, driving the development of various FGFR inhibitors. Despite clinical advances, therapeutic efficacy remains limited by the emergence of drug resistance, primarily mediated by gatekeeper mutations in FGFRs. To overcome this challenge, we designed and synthesized a novel series of 7-(1-methyl-1-indole-3-yl)-5-pyrrolo[2,3-]pyrazine derivatives as covalent pan-FGFR inhibitors targeting both wild-type and gatekeeper mutants. Compound demonstrated potent nanomolar inhibitory activity against FGFR1-3 and gatekeeper mutants in biochemical and cellular assays. Structural characterization using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF-MS) and X-ray crystallography confirmed covalent binding of to FGFR1. Additionally, showed significant in vivo antitumor efficacy in nude mice bearing the RT112 bladder cancer xenograft model. These findings establish as a promising lead for further development of FGFR-targeted anticancer therapies.
PubMed: 40921092
DOI: 10.1021/acs.jmedchem.5c01594
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.88 Å)
構造検証レポート
Validation report summary of 9uhc
検証レポート(詳細版)ダウンロードをダウンロード

242842

件を2025-10-08に公開中

PDB statisticsPDBj update infoContact PDBjnumon